Skip to main content

An update on an incident involving one of our systems

Hide
Quest Diagnostics

Evaluation of Current Screening Thresholds for the Detection of Primary Aldosteronism

Evaluation of Current Screening Thresholds for the Detection of Primary Aldosteronism

Authors: Voorhies KR, Bi C, Adeyemo MA, Dixit SB, Vaidya A, McPhaul MJ, Marcelli M

Citation: Hypertension. 2026 Sep 17. doi: 10.1161/HYPERTENSIONAHA.126.27634. Online ahead of print.

Specialties: Cardiology, Cardiovascular, Endocrinology

Related content

FAQ
Primary Aldosteronism (PA)
Audio Podcast
Instant insights: Rethinking Primary Aldosteronism Diagnosis
Publication
Comparing ARR Versus Suppressed PRA as Screening Tests for Primary Aldosteronism
Audio Podcast
Unpacking Primary Aldosteronism: New Insights and Advances in Diagnosis

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.